8-K current report · filed Nov 16, 2026

Biohaven Ltd. (BHVN) 8-K Current Report: November 16, 2026

Item 7.01Item EX-99.1BHVN overview

Short answer

Biohaven Ltd. (BHVN) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor presentation at Jefferies Global Healthcare Conference, London, November 16-19.

Biohaven Ltd. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Investor presentation at Jefferies Global Healthcare Conference, London, November 16-19
  • Exhibit 99.1 contains Biohaven’s conference materials, potentially relevant for pipeline and corporate updates

Item EX-99.1 · Exhibit EX-99.1

  • November 2026 corporate presentation highlights Biohaven’s protein-degrader platform and broad pipeline across autoimmune disease, epilepsy, pain, oncology, and neurology
  • BHV-1300 Graves’ disease Phase 3 initiated, following preliminary data showing over 80% TSHR autoantibody reduction and hormone normalization within 3 to 5 weeks
  • BHV-1400 IgA nephropathy Phase 3 planned for 2026, with 500 mg dosing and 420 planned participants across treatment and placebo arms
  • Protein-degrader platform claims over 2M addressable U.S. patients, 8+ programs, and $30B+ combined peak-sales potential, all management estimates
  • Opakalim data showed median time to second generalized tonic-clonic seizure of 141 days versus 47 days for placebo, but the study terminated early for strategic prioritization

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Biohaven Ltd. 8-K filings

Get the next BHVN 8-K as it lands

Follow BHVN for push alerts, or ask the research agent what this filing means.